Moderately bullish activity in Hims and Hers Health (HIMS), with shares up $1.04, or 2.72%, near $39.45. Options volume relatively light with 24k ...

Marketers are positioning weight-loss shots as cosmetic elixirs for anyone who wants to lose a few pounds. Doctors warn that ...

The discounts should be compared against the drugs’ “ultimate net price” rather than their indicated list price to gauge the ...

In a crowded GLP-1 race dominated by giants, retail traders are siding with Novo Nordisk for the long haul, according to a ...

Within the healthcare space, one company that combines fundamental safety with the high growth rates typically found in ...

Novo Nordisk's highly anticipated but ultimately unsuccessful Alzheimer's trials were a long shot for the maker of ...

A next-generation treatment from Novo Nordisk helped patients with diabetes lower their blood sugar and lose weight in a ...

The pharma giant said amycretin helped patients lose weight and reduce blood-sugar levels in pill and injection forms during ...

Novo Nordisk is hitting the gas on amycretin development. After posting phase 2 data, the company has decided to run pivotal ...

Novo Nordisk stock price has suffered a harsh reversal this year as the company’s woes have escalated. What next for the stock?

A glimmer of hope for Alzheimer’s patients vanished Monday, when Novo Nordisk said a trial of an oral version of its weight ...